For ovarian cancer. Sold as Cytalux. Every FDA application for this active ingredient. Orphan exclusivity to Nov 29, 2028
As of Nov 22, 2026, FDA lists 1 application for Pafolacianine sodium (sold as Cytalux), first approved Nov 29, 2021, with 1 new use approved and 0 published complete response letters.
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Nov 29, 2021 | CytaluxNDA 214907 · New molecular entity | On Target Laboratories | 1 | Marketed |
| Study | Phase | Status | Posted |
|---|---|---|---|
| An Imaging Agent (Pafolacianine) for Identifying Lesions in Pediatric Patients With Primary or Metastatic Solid TumorsChildhood Malignant Solid Neoplasm, Childhood Malignant Thoracic Neoplasm · Mayo Clinic | Phase 3 | Recruiting | Apr 8, 2025 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Mechanisms, targets, withdrawals and boxed warnings are from ChEMBL (EMBL-EBI, CC BY-SA 3.0), matched by ingredient name. How trials ended is TrialPanorama's classification of ClinicalTrials.gov records (Wang et al. 2025, Apache-2.0), matched by the intervention name each trial registered. Drugs@FDA